(NASDAQ: RGNX)
NEW YORK, Jan. 29, 2026 /PRNewswire/ — Levi & Korsinsky, LLP is investigating Regenxbio Inc. (NASDAQ: RGNX) regarding potential gaps between information provided to investors and underlying safety developments in the company’s gene therapy clinical programs. Shareholders who purchased RGNX shares and lost money may click here to learn about their legal rights.
On January 28, 2026, Regenxbio disclosed via Form 8-K that the FDA placed clinical holds on its RGX-111 and RGX-121 programs following the identification of a tumor in a trial participant. The disclosure prompted a 30-35% decline in the company’s share price.
SEC disclosure rules require public companies to provide investors with material information necessary to make informed investment decisions. Item 8.01 of Form 8-K permits companies to disclose material events not specifically covered by other items. Rule 10b-5 under the Securities Exchange Act of 1934 prohibits material misstatements and omissions in connection with securities transactions. The regulation encompasses not only affirmative false statements but also the omission of facts necessary to make other statements not misleading.
During the Q3 2025 earnings call on November 6, 2025, CEO Curran Simpson highlighted positive regulatory interactions, stating: “The FDA completed inspections of our clinical sites and in-house manufacturing facility with no observations, a rare and significant achievement.” The emphasis on favorable inspection results without corresponding disclosure of safety concerns being evaluated by the agency created an asymmetric presentation of the company’s regulatory standing.
Notably, the Q3 2025 earnings call transcript contains no discussion of the RGX-111 program for MPS I, despite this program being a material pipeline asset that would later be subject to the same FDA clinical hold. The absence of any update on this program during a quarterly investor communication raises questions about the completeness of the information provided to shareholders.
RGNX investors who wish to discuss this investigation may contact the firm by clicking here. There is no cost or obligation.
Levi & Korsinsky maintains a national securities practice with offices in New York, California, Connecticut, and D.C. Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Joseph E. Levi, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Email: jlevi@levikorsinsky.com
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/investigation-into-regenxbio-questions-arise-over-disclosure-completeness-prior-to-fda-action-302674544.html
SOURCE Levi & Korsinsky, LLP
